Fig. 1: CRISPR/Cas9 screening links SMARCA4 to ferroptosis.

a Schematic outline of the CRISPR/Cas9 RSL3 screening workflow in PC9 cell line. Created in BioRender. Bi, G. (2025) https://BioRender.com/fjloxzm. b CRISPR/Cas9 screening results of several genes of interests and well-established ferroptosis regulators. c SMARCA4 protein levels in PC9, H1975, HCC827, A549 and H23 NSCLC cell lines determined by western blotting. d SMARCA4 protein levels in Cas9-NC and SMARCA4-KO PC9, H1975, HCC827 cells determined by western blotting. e Cell viability in Cas-NC and SMARCA4-KO PC9, H1975 and HCC827 cells treated with RSL3 for 6 h. f SMARCA4 protein levels in A549 and H23 cells with indicated genotypes determined by western blotting. g Cell viability in A549 and H23 with indicated genotypes treated with 1000 nM RSL3 for 6 h. h Cell viability in A549 and H23 cells with indicated genotypes treated with 1000 nM RSL3 combined with or without DFO (100 μM), Fer-1 (10 μM), z-VAD-FMK (10 μM), or necrosulfonamide (0.5 μM) for 6 h. i Lipid peroxidation in PC9 and A549 cells with indicated genotypes treated with RSL3 (PC9: 200 nM; A549: 1000 nM) for 3 h. j Transmission electron microscopy images of A549 cells with indicated genotypes treated with 1000 nM RSL3 for 4 h. Scale bars: 4 μm. k Representative brightfield images of patient-derived organoids treated with 10 μM RSL3 for 96 h. Scale bars: 100 μm. Data are presented as the mean ± SD, n = 3 independent experiments. Consistent results were observed across three biological replicates in (c, d, f, j, k). Unpaired two-tailed Student’s t-tests are used. Source data are provided as a Source Data file.